[
  {
    "ts": "2026-02-19T01:14:13+00:00",
    "headline": "The Bull Case For Charles River Laboratories (CRL) Could Change Following 2025 Losses And New Leadership Appointments",
    "summary": "Charles River Laboratories International reported fourth-quarter 2025 revenue of US$994.23 million with a net loss of US$276.56 million, alongside full-year 2025 revenue of US$4.02 billion and a net loss of US$144.34 million driven in part by sizeable goodwill and intangible asset impairments. At the same time, the company issued 2026 guidance calling for at least flat to 1.5% revenue growth and GAAP EPS of US$6.30–US$6.80, while appointing veteran healthcare finance executive Glenn G...",
    "url": "https://finance.yahoo.com/news/bull-case-charles-river-laboratories-011413073.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d8905e41-7c6d-36d5-964a-86870f4374ca",
      "content": {
        "id": "d8905e41-7c6d-36d5-964a-86870f4374ca",
        "contentType": "STORY",
        "title": "The Bull Case For Charles River Laboratories (CRL) Could Change Following 2025 Losses And New Leadership Appointments",
        "description": "",
        "summary": "Charles River Laboratories International reported fourth-quarter 2025 revenue of US$994.23 million with a net loss of US$276.56 million, alongside full-year 2025 revenue of US$4.02 billion and a net loss of US$144.34 million driven in part by sizeable goodwill and intangible asset impairments. At the same time, the company issued 2026 guidance calling for at least flat to 1.5% revenue growth and GAAP EPS of US$6.30–US$6.80, while appointing veteran healthcare finance executive Glenn G...",
        "pubDate": "2026-02-19T01:14:13Z",
        "displayTime": "2026-02-19T01:14:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Ih9Jyeb4E8RAOq22ZtFHA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r5jgPUxQrxmcesBmGBKgkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-charles-river-laboratories-011413073.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-charles-river-laboratories-011413073.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T14:12:12+00:00",
    "headline": "Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness",
    "summary": "Event context and recent stock performance Without a specific headline event driving today’s move, Charles River Laboratories International (CRL) is drawing attention after a one-month return of about a 28% decline and a year-to-date decline near 22%. See our latest analysis for Charles River Laboratories International. The recent 30 day share price return of a 28.08% decline, alongside a year to date share price return of a 21.94% decline, contrasts with a 1 year total shareholder return of...",
    "url": "https://finance.yahoo.com/news/assessing-charles-river-laboratories-crl-141212012.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e512f192-0801-38df-949a-91c01e55bc8f",
      "content": {
        "id": "e512f192-0801-38df-949a-91c01e55bc8f",
        "contentType": "STORY",
        "title": "Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness",
        "description": "",
        "summary": "Event context and recent stock performance Without a specific headline event driving today’s move, Charles River Laboratories International (CRL) is drawing attention after a one-month return of about a 28% decline and a year-to-date decline near 22%. See our latest analysis for Charles River Laboratories International. The recent 30 day share price return of a 28.08% decline, alongside a year to date share price return of a 21.94% decline, contrasts with a 1 year total shareholder return of...",
        "pubDate": "2026-02-19T14:12:12Z",
        "displayTime": "2026-02-19T14:12:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Ih9Jyeb4E8RAOq22ZtFHA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r5jgPUxQrxmcesBmGBKgkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-charles-river-laboratories-crl-141212012.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-charles-river-laboratories-crl-141212012.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T05:33:55+00:00",
    "headline": "CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers",
    "summary": "Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $994.2 million. Its non-GAAP profit of $2.39 per share was 1.9% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/crl-q4-deep-dive-flat-053355892.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "4ea44d40-df58-3b2b-a356-0743b45b7812",
      "content": {
        "id": "4ea44d40-df58-3b2b-a356-0743b45b7812",
        "contentType": "STORY",
        "title": "CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers",
        "description": "",
        "summary": "Lab services company Charles River Laboratories (NYSE:CRL) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $994.2 million. Its non-GAAP profit of $2.39 per share was 1.9% above analysts’ consensus estimates.",
        "pubDate": "2026-02-19T05:33:55Z",
        "displayTime": "2026-02-19T05:33:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/7509c571642c6ae9d1577bc3c4457c17",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "CRL Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PLZRbui545u2bOcqTkunEw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/7509c571642c6ae9d1577bc3c4457c17.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YlRDliezLyxJ3r.biO59fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/7509c571642c6ae9d1577bc3c4457c17.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crl-q4-deep-dive-flat-053355892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crl-q4-deep-dive-flat-053355892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]